Disruptive Artificial Intelligence engine to facilitate rapid low cost development of specialist e-health applications for smart decision making in medical pre-diagnosis

Project Information

Al-medicare

Grant agreement ID: 762032

DOI

10.3030/762032

Project closed

EC signature date 4 February 2017

Start date 1 February 2017

End date 31 May 2017

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

INFERMEDICA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
Poland

Periodic Reporting for period 1 - Al-medicare (Disruptive Artificial Intelligence engine to facilitate rapid low cost development of specialist e-health applications for smart decision making in medical pre-diagnosis)

Reporting period: 2017-02-01 to 2017-05-31

Summary of the context and overall objectives of the project

The purpose of the actions defined in our Work Plan have been achieved. We are assured that our disruptive Artificial Intelligence engine can facilitate rapid low cost development of specialist e-health applications for smart decision making in medical pre-diagnosis moreover as a patient triage AI solution can help save patients from self-misdiagnosis and can optimize utilization of resources by cutting off redundancies.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We have conducted technical and technological feasibility study (Task 1) including elaborated Medical Conditions Listing for our Medical knowledge base which is one of the most important component of Infermedica’s platform, technical assessment of the solution including: interface engine; Probabilistic modelling, Machine learning based on real patient diagnoses, Bayesian adjustment of condition prevalence model based on real patient diagnoses that includes: Variational inference in Bayesian Network, Combined Bayesian and classification models The objective was to outline the Automatic verification of the medical content process and we described it. We have accelerated partnership relations with potential partners and customers and prepared a work plan which defines the actions that we are going to undertake in SME Instrument phase 2 project either from technical and business perspective.

Moreover, we have conducted market and commercial study (Task 2) including deep market study, Innovation Management Strategy/IPR study and actions focused on market demonstration and market uptake.

Based on the results and information gathered we have updated our initial business. Now we are ready to bring the product into the market considering all costs associated and profitability.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Phase 1 execution proved that our innovative project is feasible and has a commercial value. The solution will help save patients from self-misdiagnosis and will optimize utilization of resources by cutting off redundancies Patient triage AI can contribute to achieving universal health coverage as well as divert into educational function. Due to technological development, people are still keen on self-diagnosing themselves online. Being unsupervised by the specialist makes the whole activity less predictable and puts them in position to hurt themselves or generate unnecessary physician office visits. Shortage of doctors, especially in the US, is going to deepen by 2030. Physicians would have to choose to either work long hours or limit number of treated patients. At the same time, digital health market growth will be positively influenced by population aging, patient empowerment, more common access to new media and healthcare privatization. Legal factors and people habits will inhibit the progres Currently the competitors can be divided into two distinct groups: big data analyzers and triage-communication based solutions. Main customers for the solution would include health insurers, health providers and software developers. In OECD countries, 280 private insurance companies, 2400 private for profit hospitals and 1400 healthtech startups might be early adopters of AI-based technology

Value proposition